- Resverlogix Corp. (TSX: RVX, OTC: RVXCF) held its Annual Meeting of Shareholders on June 30, 2025, in Calgary, where four board members were elected with high approval ratings.
- Siu Lun To received the highest approval rating at 97.11%, among other board members elected with over 96% approval.
- All resolutions from the May 16, 2025, Notice of Meeting and Management Information Circular were approved by shareholders.
Resverlogix Corp. (TSX: RVX, OTC: RVXCF) successfully conducted its Annual Meeting of Shareholders on June 30, 2025, in Calgary, Alberta. The meeting was a key milestone for the company as it saw the election of four board members with strong approval ratings, signaling robust shareholder confidence.
The elected board members include Donald J. McCaffrey with 96.55% approval, Kelly McNeill with 96.79% approval, Siu Lun To who received the highest approval of 97.11%, and Kenneth Zuerblis with 96.94% approval. This demonstrates a solid consensus among shareholders regarding the leadership team.
Additionally, all resolutions outlined in the Notice of Meeting and Management Information Circular dated May 16, 2025, were successfully approved by the shareholders. This includes strategic directives that will guide Resverlogix's future efforts in its core areas of epigenetic therapies.
Resverlogix continues to be a front-runner in biotechnology, focusing on developing epigenetic therapies aimed at regulating disease-causing gene expressions. With a key focus on the treatment of cardiovascular diseases and associated comorbidities, Resverlogix is pioneering clinical programs evaluating its lead candidate, apabetalone.
The company has partnered with EVERSANAâ„¢ for the commercialization of its therapies in Canada and the United States, further strengthening its market position. Resverlogix's common shares are actively traded on the Toronto Stock Exchange under the ticker RVX.
